Navigation Links
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy

BOTHELL, WA – June 25 – MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of Vascana – a topical formulation designed to treat Raynaud’s Disease.

The study met its primary end point and demonstrated statistical significance, with p = 0.008 for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups.

“With the conclusion of this clinical study, MediQuest is one step closer to submitting the Vascana New Drug Application to the FDA,” said MediQuest President and CEO Dr. Frederick Dechow. “If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud’s symptoms, providing clinicians with a needed treatment for patients.”

Vascana has the potential of satisfying an unmet medical need for more than 2 million Americans seeking care for Raynaud’s Disease.

In addition to Vascana, MediQuest’s ongoing developmental efforts have generated a robust pipeline that includes three drug candidates in clinical trials, one at the pre-clinical stage and others at the research stage. The company develops first- and best-in-class topical therapies to treat patients suffering from inflammatory and infectious diseases.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis and actinic keratosis.

In addition to his
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... has announced the addition of the "Deciphering ... Strategies" report to their offering. ... pharmaceutical companies have been involved in a series ... patent cliff has resulted in significant overcapacities in ...
(Date:7/7/2015)... , 7. Juli 2015 BioClinica®, ... für klinische Studien, gab heute bekannt, dass es ... Unternehmen bei Gewinnung und Erhalt von Patienten übernommen ... MediciGlobal , Ltd. und Access to Patients, ... einen Dienst zum Auffinden von Patienten, die für ...
(Date:7/7/2015)... July 7, 2015   InspireMD, Inc. ... leader in embolic protection systems ("EPS"), today announced ... System integrated with MicroNet ™ has received ... New Product Innovation Award.  Through active market research ... and consultants recognize the successful introduction of new ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5
... 17, 2010 Mylan Inc. (Nasdaq: MYL ) ... Inc. have been sued by Shionogi Pharma Inc. and CIMA ... New Drug Application (ANDA) with the U.S. Food and Drug ... mg, 15 mg and 30 mg. This product is the ...
... Dr. Marisa Weiss, president and founder of Breastcancer.org ... a letter to the U.S. Food and Drug Administration ... to review data for Avastin,s use in metastatic HER2-negative ... FDA has recommended removing Avastin,s approval to treat breast ...
Cached Medicine Technology:Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT® 2Non-Profit Breastcancer.org Shares Concerns with FDA on Avastin Breast Cancer Recommendation 2Non-Profit Breastcancer.org Shares Concerns with FDA on Avastin Breast Cancer Recommendation 3
(Date:7/7/2015)... , ... July 07, 2015 , ... Difass USA, a ... help pass those long, stressful days at work is knowing that there is hopefully ... laid back and stress free as imagined. Planning for a vacation can be quite ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 ... ... International Business Times highlights rumors about possible facial rejuvenation that have emerged about ... year-old former U.S. Secretary of State looks more youthful than she has in ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the ... helps active people find the most fun activities to do with friends. , The ... It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... only industry group whose board is limited to permit holders. The Medical Cannabis ... how to move the industry forward and are committed to making sure patients ...
(Date:7/7/2015)... ... July 07, 2015 , ... At the end of June Pacific Prime Renewals team in Hong ... This initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only reduce but ... this initiative Cotton explained, “We send anything between 300 and 600 pieces of paper per ...
Breaking Medicine News(10 mins):Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2
... prepare for a day without cigarettes and tobacco products ... Smokeout (R) (November 21), new research gives them more ... to the American Academy of Otolaryngology-Head and Neck Surgery ... organization,s annual meeting in September 2008 are studies that ...
... Nelson, PhD, served as vice-chair of the advisory committee ... by the U.S. Department of Health and Human Services ... for Physical Activity and Nutrition and Associate Professor of ... Policy at Tufts. , "After reviewing a ...
... A further new multidisciplinary journal in the neurosciences, ... March 2009. With this addition to its publishing ... of research, current practices and future trends in the ... the gap between the life sciences, social sciences, engineering, ...
... Institute have found that reducing the levels of vascular endothelial ... of new blood vessel growth, in adult mice causes the ... retina that are essential to visual function. This finding, published ... implications for the chronic use of promising new anti-VEGF drugs ...
... WOBURN, Mass., Nov. 3 Culbert Healthcare,Solutions, ... services firm, announced today that Norm Botsford ... the Strategic Services practice., Mr. Botsford ... Officer,at University Physicians Healthcare (UPH), the health ...
... Scientists at Schepens Eye Research,Institute have found that reducing ... best known as a stimulator of new blood,vessel growth, ... Muller,glia -- cells of the retina that are essential ... 2008 PLoS ONE, holds implications for,the chronic use of ...
Cached Medicine News:Health News:Smokers see decline in ability to smell, rise in laryngitis, and upper airway issues 2Health News:Tufts' Nelson a leader on Physical Activity Guidelines advisory committee 2Health News:Springer launches Cognitive Computation 2Health News:Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution 2Health News:Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution 3Health News:Norm Botsford Joins Culbert Healthcare Solutions' Strategic Services Team 2Health News:Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution 2Health News:Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: